HYQVIA
openFDA label record#
This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.
Verified complete openFDA source JSON
- Brand name
- HYQVIA
- Generic name
- IMMUNE GLOBULIN INFUSION (HUMAN), 10% WITH RECOMBINANT HUMAN HYALURONIDASE
- Manufacturer
- Takeda Pharmaceuticals America, Inc.
- Product type
- PLASMA DERIVATIVE
- SPL set ID
- 7ca2c26f-4be2-48cd-be5b-486e350654ba
- SPL ID
- 23f408f3-d160-4864-afe2-8d112a951887
- Version
- 23
- Effective date
- 2026-06-18
- Source export date
- 2026-11-13
- Source partition
- 2
- Source file
- https://download.open.fda.gov/drug/label/drug-label-0002-of-0014.json.zip
- Source object key
- raw/openfda/drug-label/2026-11-13/3b4204ed830f35b16ab24b2123672d7d93066eb0fd8af1cf09b223d0e4568221/drug-label-0002-of-0014.json.zip
- Source manifest SHA-256
- 8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
- Import run
- 20261116T150851Z
- Imported at
- 2026-11-16 15:31:45
Harmonized identifier links#
Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.
| Type | Scope | Identifier | Source field |
|---|---|---|---|
| application applno | BLA | 125402 | derived:openfda.application_number |
| application number | BLA125402 | openfda.application_number | |
| brand name | HYQVIA | openfda.brand_name | |
| generic name | IMMUNE GLOBULIN INFUSION (HUMAN), 10% WITH RECOMBINANT HUMAN HYALURONIDASE | openfda.generic_name | |
| manufacturer name | Takeda Pharmaceuticals America, Inc. | openfda.manufacturer_name | |
| ndc | package | 0944-2715-25 | openfda.package_ndc |
| ndc | package | 0944-2514-02 | openfda.package_ndc |
| ndc | package | 0944-2723-03 | openfda.package_ndc |
| ndc | package | 0944-2718-20 | openfda.package_ndc |
| ndc | package | 0944-2716-05 | openfda.package_ndc |
| ndc | package | 0944-2513-02 | openfda.package_ndc |
| ndc | package | 0944-2717-10 | openfda.package_ndc |
| ndc | package | 0944-2724-03 | openfda.package_ndc |
| ndc | package | 0944-2719-30 | openfda.package_ndc |
| ndc | package | 0944-2512-02 | openfda.package_ndc |
| ndc | package | 0944-2722-03 | openfda.package_ndc |
| ndc | package | 0944-2721-03 | openfda.package_ndc |
| ndc | package | 0944-2511-02 | openfda.package_ndc |
| ndc | package | 0944-2510-02 | openfda.package_ndc |
| ndc | package | 0944-2720-03 | openfda.package_ndc |
| ndc | product | 0944-2512 | openfda.product_ndc |
| ndc | product | 0944-2511 | openfda.product_ndc |
| ndc | product | 0944-2510 | openfda.product_ndc |
| ndc | product | 0944-2514 | openfda.product_ndc |
| ndc | product | 0944-2513 | openfda.product_ndc |
| ndc11 | package | 00944251402 | derived:openfda.package_ndc |
| ndc11 | package | 00944271820 | derived:openfda.package_ndc |
| ndc11 | package | 00944271605 | derived:openfda.package_ndc |
| ndc11 | package | 00944251102 | derived:openfda.package_ndc |
| ndc11 | package | 00944271930 | derived:openfda.package_ndc |
| ndc11 | package | 00944272203 | derived:openfda.package_ndc |
| ndc11 | package | 00944271525 | derived:openfda.package_ndc |
| ndc11 | package | 00944272403 | derived:openfda.package_ndc |
| ndc11 | package | 00944251302 | derived:openfda.package_ndc |
| ndc11 | package | 00944271710 | derived:openfda.package_ndc |
| ndc11 | package | 00944272303 | derived:openfda.package_ndc |
| ndc11 | package | 00944251202 | derived:openfda.package_ndc |
| ndc11 | package | 00944272003 | derived:openfda.package_ndc |
| ndc11 | package | 00944251002 | derived:openfda.package_ndc |
| ndc11 | package | 00944272103 | derived:openfda.package_ndc |
Boxed warning cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
WARNING: THROMBOSIS Thrombosis may occur with immune globulin products, including HYQVIA. Risk factors may include advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling vascular catheters, hyperviscosity and cardiovascular risk factors. Thrombosis may occur in the absence of known risk factors. [see Warnings and Precautions (5.2) ] For patients at risk of thrombosis, administer HYQVIA at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. [see Warnings and Precautions (5.2) ] Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk of hyperviscosity. [see Warnings and Precautions (5.2) ] WARNING: THROMBOSIS See full prescribing information for complete boxed warning . Thrombosis may occur with immune globulin products, including HYQVIA. Risk factors may include advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling vascular catheters, hyperviscosity and cardiovascular risk factors. ( 5.2 ) For patients at risk of thrombosis, administer HYQVIA at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. ( 5.2 ) Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk of hyperviscosity. ( 5.2 )
Warnings cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
warnings and cautions
5 WARNINGS AND PRECAUTIONS IgA-deficient patients with anti-IgA antibodies are at greater risk of severe hypersensitivity and anaphylactic reactions. ( 5.1 ) Thrombosis may occur following treatment with immune globulin products including HYQVIA. ( 5.2 ) Antibodies to rHuPH20 can develop. The potential exists for such antibodies to cross-react with endogenous Hyaluronidase (PH20) which is known to be expressed in the adult male testes, epididymis, and sperm. It is unknown whether these antibodies may interfere with fertilization in humans. The clinical significance of these antibodies is not known. ( 5.3 ) Aseptic Meningitis Syndrome (AMS) may occur. Discontinue treatment if AMS symptoms appear. ( 5.4 ) Acute intravascular hemolysis may occur. Monitor for clinical signs and symptoms of hemolysis and hemolytic anemia. ( 5.5 ) Infusion into or around an infected area can spread a localized infection. ( 5.7 ) Monitor for pulmonary adverse reactions (transfusion-related acute lung injury [TRALI]). ( 5.8 ) May carry a risk of transmitting infectious agents, e.g., viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent. ( 5.9 ) 5.1 Hypersensitivity Reactions Severe hypersensitivity reactions may occur after treatment with immune globulin products, including HYQVIA, even in patients previously treated with immune globulin products. In case of hypersensitivity, discontinue the HYQVIA infusion immediately and institute appropriate treatment. Immune Globulin Infusion (Human), 10% of HYQVIA contains IgA (average concentration of 37µg/mL). Patients with antibodies to IgA potentially are at greater risk of developing potentially severe hypersensitivity and anaphylactic reactions. 5.2 Thrombosis Thrombosis has been reported to occur following treatment with immune globulin products, including HYQVIA. Risk factors may include advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling central vascular catheters, hyperviscosity, and cardiovascular risk factors. Thrombosis may occur in the absence of known risk factors. Ensure adequate hydration in patients before administration of HYQVIA. For patients at risk of thrombosis, administer HYQVIA at the minimum dose and infusion rate practicable. Monitor patients for signs and symptoms of thrombosis. Consider baseline assessment of blood viscosity in patients at risk for hyperviscosity, such as those with cryoglobulins, fasting chylomicronemia/markedly high triacylglycerols (triglycerides), or monoclonal gammopathies. [see Boxed Warning , Dosage and Administration (2) ] . 5.3 Immunogenicity of rHuPH20 Eighteen percent (15 of 83) of patients receiving HYQVIA in PID clinical studies developed non-neutralizing antibodies to the rHuPH20 component. The potential exists for such antibodies to cross-react with endogenous Hyaluronidase (PH20), which is known to be expressed in the adult male testes, epididymis, and sperm. It is unknown whether these antibodies can interfere with fertilization in humans. The clinical significance of these antibodies is not known. Clinical studies in CIDP based on 4,729 rHuPH20 infusions in 132 patients revealed three incidences in two subjects of anti-rHuPH20 neutralizing antibody positivity. Elevation in neutralizing antibody titers was transient and occurred at three measurements over a 6-year follow-up period. No efficacy or safety issues were identified with the occurrence of neutralizing antibody positivity. 5.4 Aseptic Meningitis Syndrome Aseptic meningitis syndrome (AMS) may occur with immune globulin products, including HYQVIA. Signs and symptoms of AMS include severe headache, nuchal rigidity, drowsiness, fever, photophobia, painful eye movements, nausea and vomiting. AMS usually begins within several hours to 2 days following immune globulin treatment. Conduct neurological examination on patients exhibiting symptoms and signs of AMS, including Cerebrospinal fluid (CSF) studies, to rule out other causes of meningitis. CSF studies frequently reveal pleocytosis up to several thousand cells per cubic millimeter, elevated protein levels up to several hundred mg/dL, and negative culture results. Discontinuation of IgG treatment has resulted in remission of AMS within several days without sequelae. 5.5 Hemolysis Hemolysis may occur with immune globulin products, including HYQVIA due to the presence of blood group antibodies that may act as hemolysins and induce in vivo coating of red blood cells (RBC). This may cause a positive direct antiglobulin test [DAT (Coombs test)]. Delayed hemolytic anemia can develop after HYQVIA therapy due to enhanced RBC sequestration [see Adverse Reactions (6) ]. Monitor patients for signs and symptoms of hemolysis. If signs and symptoms of hemolysis are observed, perform additional confirmatory laboratory testing. 5.6 Renal Injury Renal injury including acute renal failure, acute tubular necrosis, proximal tubular nephropathy, and osmotic nephrosis may occur after treatment with immune globulin products, including HYQVIA. Ensure patients are not volume depleted before administering HYQVIA. In patients who are at risk of renal injury because of pre-existing renal insufficiency or predisposition to acute renal failure (such as diabetes mellitus, age greater than 65, volume depletion, sepsis, paraproteinemia, or patients receiving known nephrotoxic drugs, etc.), administer HYQVIA at the minimum rate of infusion practicable [see Dosage and Administration (2.3) ]. Assess renal function, including measurement of blood urea nitrogen (BUN), serum creatinine, and urine output in patients receiving HYQVIA prior to initial infusion and at appropriate intervals thereafter. If renal function deteriorates, consider discontinuation of HYQVIA [see Dosage and Administration (2.3) ]. 5.7 Spread of Localized Infection Infusion into or around an infected area can spread a localized infection. Do not infuse HYQVIA into these areas due to potential risk of spreading a localized infection. 5.8 Transfusion-Related Acute Lung Injury Transfusion-Related Acute Lung Injury (TRALI) may occur with intravenously administered immune globulin products symptoms typically occur within 1 to 6 hours after treatment and may include severe respiratory distress, pulmonary edema, hypoxemia, normal left ventricular function, and fever. Monitor patients for signs and symptoms of TRALI. If TRALI is suspected, conduct an evaluation, including appropriate tests for the presence of anti-neutrophil and anti-HLA antibodies in both the product and patient serum. Manage patients using oxygen therapy with ventilatory support as appropriate. 5.9 Transmissible Infectious Agents There is risk of transmission of infectious disease or agents including viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent, and the Creutzfeldt-Jakob disease agent with HYQVIA administration because it is manufactured using human blood. The risk of infectious agent transmission is minimized by plasma donor screening, donation testing, and manufacturing steps proven to inactivate and remove bloodborne pathogens. Report all infections thought to be possibly transmitted by HYQVIA to Takeda Pharmaceuticals U.S.A., Inc. at 1-877-TAKEDA-7 ( 1-877-825-3327 ) (In the U.S.). 5.10 Interference with Laboratory Tests After infusion of IgG, the transitory rise of the various passively transferred antibodies in the patient’s blood may yield false positive serological testing results, with the potential for misleading interpretation. Passive transmission of antibodies to erythrocyte antigens (e.g., A, B, and D) may cause a positive direct or indirect antiglobulin (Coombs’) test. Infusions of immune globulin products can lead to false positive readings in assays that depend on detection of ß-D-glucans for diagnosis of fungal infections; this may persist during the weeks following infusion of the product.
Adverse reactions cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
adverse reactions
6 ADVERSE REACTIONS PI: The most common adverse reactions observed in >5% of patients were local reactions, headache, antibody formation against rHuPH20, fatigue, nausea, pyrexia, and vomiting. ( 6 ) CIDP: The most common adverse reactions observed in >5% of patients were local reactions, headache, pyrexia, nausea, fatigue, erythema, pruritus. ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Takeda Pharmaceuticals U.S.A., Inc. at 1-877-TAKEDA-7 (1-877-825-3327) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in clinical studies of a product cannot be directly compared to rates in the clinical studies of another product and may not reflect the rates observed in clinical practice. Primary Immunodeficiency (PI) Immune Globulin Infusion (Human), 10% administered intravenously: Prior to initiation of treatment with HYQVIA, 87 patients received 365 infusions of Immune Globulin Infusion (Human), 10% encompassing 22.2 patient-years. Among the 87 patients treated, 56 (64.4%) experienced 1 or more adverse reactions. Among the 365 intravenous infusions, 158 adverse reactions occurred for a rate per infusion of 0.43. A total of 1,359 infusions of HYQVIA were administered during the trial; 230 of these infusions occurred during the ramp-up period and the other 1,129 occurred during the observation period. During the observation period, 81 patients received 1,129 infusions of HYQVIA; of those, 67 (82.7%) experienced one or more adverse reactions. Among the 1,129 HYQVIA infusions, 456 adverse reactions occurred for a rate per infusion of 0.40. Seven of these adverse reactions were severe, defined as marked impairment of function, can lead to temporary inability to resume normal life pattern, requires prolonged intervention and/or results in sequelae. Adverse reactions occurring in greater than 5% of patients associated with infusions of HYQVIA vs. Immune Globulin Infusion (Human), 10% given intravenously are shown in Table 6 . The majority of these adverse reactions was mild to moderate in severity and did not necessitate discontinuing the infusions. Mild is defined as transient discomfort that resolves spontaneously or with minimal intervention; moderate is defined as limited impairment of function that resolves spontaneously or with minimal intervention with no sequelae. No serious adverse reactions occurred during the HYQVIA clinical trials. Table 6: Adverse Reactions Causally related adverse events and/or temporally associated adverse events occurring within 72 hours. in greater than 5% of Patients Associated with Infusions of HYQVIA vs. Immune Globulin Infusion (Human), 10% (IGIV) Given Intravenously HYQVIA IGIV Given Intravenously Adverse Reactions Excluding infections Number of Patients (%) N= 81 Number of Adverse Reactions per Infusion (Rate Rate= total number of events divided by total number of infusions. ) N = 1129 Number of Patients (%) N=87 Number of Adverse Reactions per Infusion (Rate) N = 365 Local ARs 42 (51.9%) 234 (0.21) 4 (4.6%) 4 (0.01) Systemic ARs 55 (67.9%) 222 (0.20) 54 (62.1%) 154 (0.42) Headache 17 (21%) 40 (0.04) 22 (25.3%) 42 (0.12) Fatigue 9 (11.1%) 16 (0.01) 8 (9.2%) 10 (0.03) Nausea 6 (7.4%) 12 (0.01) 10 (11.5%) 10 (0.03) Pyrexia 6 (7.4%) 11 (0.01) 6 (6.9%) 7 (0.02) Vomiting 6 (7.4%) 11 (0.01) 5 (5.7%) 7 (0.02) Six patients, 2 children and 4 adults, withdrew from the trial during the efficacy treatment period with HYQVIA due to mild to moderate adverse reactions. One child withdrew due to local pain and one due to fever, vomiting, and headaches. Of the four adults, two withdrew due to local pain and swelling, one had moderate swelling that transiently extended from the abdominal infusion site to the genitalia, and one had back injury. Antibodies binding to rHuPH20: A total of 15 out of 83 patients in the clinical trial who were treated with HYQVIA developed an antibody capable of binding to rHuPH20. These antibodies were not capable of neutralizing rHuPH20. In the clinical trial, no temporal association between adverse reactions and the presence of antibodies capable of binding to the Recombinant Human Hyaluronidase of HYQVIA could be demonstrated. There was no increase in the incidence or severity of adverse reactions in patients who developed antibodies to rHuPH20 of HYQVIA. In all patients, antibody titers decreased despite continued treatment. The effect of exposure to antibodies capable of binding to rHuPH20 of HYQVIA for periods longer than this clinical trial has not been evaluated. The local adverse reactions are listed by frequency in Table 7 . Mild swelling around the infusion site was present in most infusions due to the large volumes infused, but in general it was not considered to be an adverse reaction unless it caused discomfort. Among the 234 local adverse reactions, three were severe (infusion site pain, infusion site swelling and infusion site edema that extended from the abdominal infusion site to the genitalia); all were transient and resolved without sequelae. More than 98% of local reactions were either mild (70.5%) or moderate (28.2%) in severity. Table 7: Most Frequent Local Adverse Reactions Reported in greater than 1% of Infusion During Treatment With HYQVIA Infusion Site Reaction Number and Rate of Reactions per Infusion (N=1129) Rate per infusion = total number of events divided by total number of infusions. Discomfort/pain 122 (0.11) Erythema 32 (0.03) Swelling/Edema 35 (0.03) Pruritus 22 (0.02) During the combined efficacy and extension trials encompassing more than 3 years, the local adverse reaction rate was 2.6 per patient-year. During the first 12-month period (months 1- 12), the rate was 3.68 local adverse reactions per patient-year. During the subsequent 12-month period (months 13-24), the rate declined to 2.12 local adverse reactions per-patient year. Finally, during the third 12-month period (months 25-36), the rate further declined to 0.37 local adverse reactions per patient-year. Sixty-six of the 68 patients who completed the efficacy clinical trial enrolled in a prospective, open-label, multicenter extension trial to assess the long-term safety and tolerability of HYQVIA. Sixty-three of 66 patients enrolled received HYQVIA and 3 received IGIV. Of the 63 patients who received HYQVIA, 48 completed the extension trial. The cumulative exposure of HYQVIA across the two trials was 188 subject-years and 2,959 infusions, and a maximum exposure of 188 weeks or up to approximately 3.5 years. There were no clinically observable changes in the skin or subcutaneous tissue in either the efficacy or extension clinical trials. Pediatric population in PI: HYQVIA was evaluated in a pivotal efficacy and safety study in 44 pediatric patients (aged 2 to 16 years of age). Results from the interim data analysis, where all patients completed 12 months of participation (one year of observation period) in the study, indicated similar safety profiles to adults [see Clinical Pharmacology (12.3) , and Clinical Studies (14.1) ] . Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) The safety of HYQVIA in adult patients with CIDP was evaluated in 104 unique patients in a randomized, placebo-controlled study ( Study 1 ) and a single-arm, open-label, extension study ( Study 2 ). A total of 4085 infusions of HYQVIA were administered during these 2 studies [see Clinical Studies (14.2) ] . Development of antibodies to rHuPH20: A total of 15 patients (14.4%) who were treated with HYQVIA in Studies 1 and 2 developed high-binding anti-rHuPH20 antibody titers (≥1:160). A total of 7 patients (11.3%) who were treated with HYQVIA in Study 1 and a total of 14 patients (16.7%) in Study 2 developed high-binding anti-rHuPH20 antibodies (≥1:160). Of the 7 patients in Study 1, 6 continued to have high-binding antibodies in Study 2, and 1 subject did not enter Study 2. Eight of the 14 patients developed high-binding antibodies during Study 2. The occurrence of high-binding antibodies was not associated with an increased rate of TEAEs. Two subjects had a transient positivity of neutralizing antibodies which were not associated with any TEAE consistent with decreased rHuPH20 effect (in Study 2 ). The binding antibody positivity rate was comparable to the rates reported in other development programs. Study 1 A total of 62 patients received HYQVIA and a total of 598 infusions of HYQVIA were administered. Adverse reactions (ARs) occurring in >5% of patients with CIDP treated with HYQVIA in Study 1 are shown in Table 8 . Table 8: Adverse Reactions Causally related adverse events and/or temporally associated adverse events occurring within 72 hours. in >5% of Patients with CIDP Treated with HYQVIA (Study 1: All Safety Patients) ARs Excluding infections HYQVIA Number of Patients (%) N = 62 HYQVIA Number of ARs per Infusion (Rate Rate=total number of events divided by total number of infusions. ) N = 598 Placebo Number of Patients (%) N=70 Placebo Number of ARs per Infusion (Rate ) N=644 AR=adverse reactions • Local ARs 17 (27.4) 103 (0.17) 5 (7.1) 13 (0.02) • Systemic ARs 18 (29.0) 44 (0.07) 7 (10.0) 14 (0.02) - Nausea 7 (11.3) 8 (0.01) 0 0 - Fatigue 5 (8.1) 7 (0.01) 1 (1.4) 1 (<0.01) - Pruritus 5 (8.1) 14 (0.02) 1 (1.4) 1 (<0.01) - Headache 4 (6.5) 9 (0.02) 5 (7.1) 12 (0.02) - Pyrexia 4 (6.5) 6 (0.01) 0 0 Blood pressure elevation was reported in 4 patients (6.5%) treated with HYQVIA in this study, including 2 patients with a history of hypertension on antihypertensive medications. Three of the 4 patients had events which were causally related and/or temporally associated (occurring within 72 hours). A total of 4 patients (3.0%) experienced adverse events (AEs) that led to discontinuation from the study; Three (3) patients in the HYQVIA group and 1 in the placebo group. The AEs leading to discontinuation in the 3 HYQVIA patients included: a cerebrovascular accident in 1 subject (who had coexisting cardiovascular risk factors), infusion site edema and infusion site pain in another subject, and nausea and chills in the third subject. The most frequent local ARs in Study 1 are listed by frequency in Table 9 . All HYQVIA local reactions (100%) were either mild (88.41%) or moderate (11.59%) in severity. Table 9: Most Frequent Local Adverse Reactions Reported in >1% of Infusion with CIDP Treated with HYQVIA (Study 1: All Safety Patients) Infusion Site Reaction HYQVIA Number of ARs per Infusion (%) N = 598 Placebo Number of ARs per Infusion (%) N = 644 AR=adverse reaction Discomfort/pain 39 (6.5%) 12 (1.9%) Swelling/edema 38 (6.4%) 6 (0.9%) Erythema 36 (6.0%) 0 Pruritus 15 (2.5%) 0 Study 2 A total of 85 patients received HYQVIA and a total of 3,487 infusions of HYQVIA were administered. Adverse reactions occurring in >5% of patients with CIDP treated with HYQVIA in Study 2 are shown in Table 10 . Table 10: Adverse Reactions Causally related adverse events and/or temporally associated adverse events occurring within 72 hours. in >5% of Patients with CIDP Treated with HYQVIA (Study 2: All Safety Patients) ARs Excluding infections Number of Patients (%) N = 85 Number of ARs per Infusion (Rate Rate=total number of events divided by total number of infusions. ) N = 3,487 AR=adverse reactions • Local ARs 16 (18.8) 362 (0.10) • Systemic ARs 27 (31.8) 197 (0.06) - Headache 17 (20.0) 78 (0.02) - Pyrexia 12 (14.1) 58 (0.02) - Nausea 7 (8.2) 9 (<0.01) - Fatigue 6 (7.1) 9 (<0.01) - Erythema 5 (5.9) 43 (0.01) Blood pressure elevation was reported in 9 patients (10.6%) in this study, including 1 subject with a history of hypertension on antihypertensive medications. Two (2) of the 9 patients had an event which was causally related and/or temporally associated (occurring within 72 hours). A total of 4 patients (4.7%) experienced AEs that led to discontinuation from the study and 1 subject (1.3%) died prior to the time of the interim analysis. The AEs leading to discontinuation in the 4 patients included mantle cell lymphoma in 1 subject, muscular weakness and worsening of CIDP in another subject, abdominal pain in the third subject, and hypoventilation in the fourth subject. The cause of death in the 1 subject was cholangiocarcinoma. The most frequent local ARs in Study 161505 are listed by frequency in Table 11 . Most of the local reactions (96.4%) were either mild (88.4%) or moderate (8.0%) in severity. Table 11: Most Frequent Local Adverse Reactions Reported in >1% of Infusion with CIDP Treated with HYQVIA (Study 2: All Safety Patients) Infusion Site Reaction Number of ARs per Infusion (%) N = 3,487 AR=adverse reaction Erythema 366 (10.5%) Swelling/edema 76 (2.2%) 6.2 Postmarketing Experience Because postmarketing reporting of adverse reactions is voluntary and from a population of uncertain size, it is not always possible to reliably estimate the frequency of these reactions or establish a causal relationship to product exposure. In addition to the adverse reactions listed above in clinical trials, the following adverse reactions have been reported in the postmarketing experience: Immune System Disorder: Hypersensitivity General Disorder and Administration Site Conditions: Influenza-like illness, Infusion site leaking Postmarketing Experience of Immune Globulin Products The following adverse reactions have been identified and reported during the postmarketing use of Immune Globulin products administered subcutaneously: Anaphylactic reaction, Tremor, Tachycardia, Hypotension, Infusion related reaction, Dyspnea, Paresthesia oral, Dermatitis allergic, Injection site rash, and Alanine aminotransferase increased.
adverse reactions table
<table width="90%" ID="table6"><caption>Table 6: Adverse Reactions<footnote>Causally related adverse events and/or temporally associated adverse events occurring within 72 hours.</footnote> in greater than 5% of Patients Associated with Infusions of HYQVIA vs. Immune Globulin Infusion (Human), 10% (IGIV) Given Intravenously</caption><col width="22%" align="left" valign="top"/><col width="17%" align="center" valign="top"/><col width="20%" align="center" valign="top"/><col width="19%" align="center" valign="top"/><col width="22%" align="center" valign="top"/><thead><tr styleCode="Botrule"><th styleCode="Rrule Lrule"/><th colspan="2" styleCode="Rrule">HYQVIA</th><th colspan="2" styleCode="Rrule">IGIV Given Intravenously</th></tr><tr><th styleCode="Rrule Lrule" align="center">Adverse Reactions<footnote>Excluding infections</footnote></th><th styleCode="Rrule">Number of Patients (%) N= 81</th><th styleCode="Rrule">Number of Adverse Reactions per Infusion (Rate<footnote>Rate= total number of events divided by total number of infusions.</footnote>) N = 1129</th><th styleCode="Rrule">Number of Patients (%) N=87</th><th styleCode="Rrule">Number of Adverse Reactions per Infusion (Rate) N = 365</th></tr></thead><tbody><tr styleCode="Botrule"><td styleCode="Rrule Lrule">Local ARs</td><td styleCode="Rrule">42 (51.9%)</td><td styleCode="Rrule">234 (0.21)</td><td styleCode="Rrule">4 (4.6%)</td><td styleCode="Rrule">4 (0.01)</td></tr><tr styleCode="Botrule"><td styleCode="Rrule Lrule">Systemic ARs</td><td styleCode="Rrule">55 (67.9%)</td><td styleCode="Rrule">222 (0.20)</td><td styleCode="Rrule">54 (62.1%)</td><td styleCode="Rrule">154 (0.42)</td></tr><tr styleCode="Botrule"><td styleCode="Rrule Lrule"> Headache</td><td styleCode="Rrule">17 (21%)</td><td styleCode="Rrule">40 (0.04)</td><td styleCode="Rrule">22 (25.3%)</td><td styleCode="Rrule">42 (0.12)</td></tr><tr styleCode="Botrule"><td styleCode="Rrule Lrule"> Fatigue</td><td styleCode="Rrule">9 (11.1%)</td><td styleCode="Rrule">16 (0.01)</td><td styleCode="Rrule">8 (9.2%)</td><td styleCode="Rrule">10 (0.03)</td></tr><tr styleCode="Botrule"><td styleCode="Rrule Lrule"> Nausea</td><td styleCode="Rrule">6 (7.4%)</td><td styleCode="Rrule">12 (0.01)</td><td styleCode="Rrule">10 (11.5%)</td><td styleCode="Rrule">10 (0.03)</td></tr><tr styleCode="Botrule"><td styleCode="Rrule Lrule"> Pyrexia</td><td styleCode="Rrule">6 (7.4%)</td><td styleCode="Rrule">11 (0.01)</td><td styleCode="Rrule">6 (6.9%)</td><td styleCode="Rrule">7 (0.02)</td></tr><tr><td styleCode="Rrule Lrule"> Vomiting</td><td styleCode="Rrule">6 (7.4%)</td><td styleCode="Rrule">11 (0.01)</td><td styleCode="Rrule">5 (5.7%)</td><td styleCode="Rrule">7 (0.02)</td></tr></tbody></table>
adverse reactions table
<table width="90%" ID="table7"><caption>Table 7: Most Frequent Local Adverse Reactions Reported in greater than 1% of Infusion During Treatment With HYQVIA</caption><col width="35%" align="left" valign="middle"/><col width="65%" align="left" valign="middle"/><thead><tr styleCode="Botrule"><th styleCode="Rrule Lrule">Infusion Site Reaction</th><th styleCode="Rrule">Number and Rate of Reactions per Infusion (N=1129)</th></tr></thead><tfoot><tr><td align="left" colspan="2">Rate per infusion = total number of events divided by total number of infusions.</td></tr></tfoot><tbody><tr styleCode="Botrule"><td styleCode="Rrule Lrule">Discomfort/pain</td><td styleCode="Rrule">122 (0.11)</td></tr><tr styleCode="Botrule"><td styleCode="Rrule Lrule">Erythema</td><td styleCode="Rrule">32 (0.03)</td></tr><tr styleCode="Botrule"><td styleCode="Rrule Lrule">Swelling/Edema</td><td styleCode="Rrule">35 (0.03)</td></tr><tr><td styleCode="Rrule Lrule">Pruritus</td><td styleCode="Rrule">22 (0.02)</td></tr></tbody></table>
adverse reactions table
<table width="90%" ID="table8"><caption>Table 8: Adverse Reactions<footnote>Causally related adverse events and/or temporally associated adverse events occurring within 72 hours.</footnote> in >5% of Patients with CIDP Treated with HYQVIA (Study 1: All Safety Patients)</caption><col width="20%" align="left" valign="middle"/><col width="20%" align="left" valign="top"/><col width="20%" align="left" valign="top"/><col width="20%" align="left" valign="top"/><col width="20%" align="left" valign="top"/><thead><tr styleCode="Botrule"><th styleCode="Rrule Lrule">ARs<footnote>Excluding infections</footnote></th><th styleCode="Rrule">HYQVIA Number of Patients (%) N = 62</th><th styleCode="Rrule Lrule">HYQVIA Number of ARs per Infusion (Rate<footnote ID="t8f1">Rate=total number of events divided by total number of infusions.</footnote>) N = 598</th><th styleCode="Rrule Lrule">Placebo Number of Patients (%) N=70</th><th styleCode="Rrule Lrule">Placebo Number of ARs per Infusion (Rate<footnoteRef IDREF="t8f1"/>) N=644</th></tr></thead><tfoot><tr><td align="left" colspan="2">AR=adverse reactions</td></tr></tfoot><tbody><tr styleCode="Botrule"><td styleCode="Rrule Lrule">• Local ARs </td><td styleCode="Rrule">17 (27.4)</td><td styleCode="Rrule">103 (0.17)</td><td styleCode="Rrule">5 (7.1)</td><td styleCode="Rrule">13 (0.02)</td></tr><tr styleCode="Botrule"><td styleCode="Rrule Lrule">• Systemic ARs</td><td styleCode="Rrule">18 (29.0)</td><td styleCode="Rrule">44 (0.07)</td><td styleCode="Rrule">7 (10.0)</td><td styleCode="Rrule">14 (0.02)</td></tr><tr styleCode="Botrule"><td styleCode="Rrule Lrule"> - Nausea</td><td styleCode="Rrule">7 (11.3)</td><td styleCode="Rrule">8 (0.01)</td><td styleCode="Rrule">0</td><td styleCode="Rrule">0</td></tr><tr styleCode="Botrule"><td styleCode="Rrule Lrule"> - Fatigue</td><td styleCode="Rrule">5 (8.1)</td><td styleCode="Rrule">7 (0.01)</td><td styleCode="Rrule">1 (1.4)</td><td styleCode="Rrule">1 (<0.01)</td></tr><tr styleCode="Botrule"><td styleCode="Rrule Lrule"> - Pruritus</td><td styleCode="Rrule">5 (8.1)</td><td styleCode="Rrule">14 (0.02)</td><td styleCode="Rrule">1 (1.4)</td><td styleCode="Rrule">1 (<0.01)</td></tr><tr styleCode="Botrule"><td styleCode="Rrule Lrule"> - Headache</td><td styleCode="Rrule">4 (6.5)</td><td styleCode="Rrule">9 (0.02)</td><td styleCode="Rrule">5 (7.1)</td><td styleCode="Rrule">12 (0.02)</td></tr><tr styleCode="Botrule"><td styleCode="Rrule Lrule"> - Pyrexia</td><td styleCode="Rrule">4 (6.5)</td><td styleCode="Rrule">6 (0.01)</td><td styleCode="Rrule">0</td><td styleCode="Rrule">0</td></tr></tbody></table>
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.